Optimal Value-Based TherapyVideo Categories: Polycythemia Vera
Supported through funding from Incyte
As we learn more about a person’s genetic makeup, the more we are able to target medicines to his/her needs and benefit. With continued research, Dr. Stainthorpe explains, we will be able to identify markers that allow us to target medicines more precisely to get better performance and reduce waste.
Ruben A. Mesa, MD, Mayo Clinic, Scottsdale Arizona describes why polycythemia vera is a difficult disease for patients to understand and what tools are important to educate. Supported through funding from Incyte